GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genenta Science SPA (NAS:GNTA) » Definitions » Capex-to-Revenue

Genenta Science SPA (Genenta Science SPA) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Genenta Science SPA Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Genenta Science SPA's Capital Expenditure for the six months ended in Dec. 2023 was $-0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


Genenta Science SPA Capex-to-Revenue Historical Data

The historical data trend for Genenta Science SPA's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genenta Science SPA Capex-to-Revenue Chart

Genenta Science SPA Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
- - - - -

Genenta Science SPA Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Genenta Science SPA's Capex-to-Revenue

For the Biotechnology subindustry, Genenta Science SPA's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genenta Science SPA's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genenta Science SPA's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Genenta Science SPA's Capex-to-Revenue falls into.



Genenta Science SPA Capex-to-Revenue Calculation

Genenta Science SPA's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.015) / 0
=N/A

Genenta Science SPA's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.001) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genenta Science SPA  (NAS:GNTA) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Genenta Science SPA Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Genenta Science SPA's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Genenta Science SPA (Genenta Science SPA) Business Description

Traded in Other Exchanges
Address
Via Olgettina No. 58, Milan, ITA, 20132
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's lead product includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.